Cynomolgus Integrin alpha L beta 2 (ITGAL&ITGB2) Heterodimer Protein, His Tag&Tag Free (MALS verified)
Cat. No. IT2-C53W3
| Molecule | Cat. No. | Product Name | Species | Host | Structure | Purity | Activity | Size&Price | Add to Cart |
|---|---|---|---|---|---|---|---|---|---|
| Integrin alpha L beta 2 | Cynomolgus Integrin alpha L beta 2 (ITGAL&ITGB2) Heterodimer Protein, His Tag&Tag Free (MALS verified) | Cynomolgus | CHO | ![]() | MALSSDS-PAGE | $485.00 100ug | |||
| Integrin alpha L beta 2 | Human Integrin alpha L beta 2 (ITGAL&ITGB2) Heterodimer Protein, His Tag&Tag Free, low endotoxin (MALS verified) | Human | CHO | ![]() | MALSSDS-PAGE | $485.00 100ug |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Alintegimod | 7HP349; 7-HP-349; 7HP-349 | Phase 2 Clinical | 7 Hills Pharma LLC | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Chagas Disease; Colorectal Neoplasms; Coronavirus Disease 2019 (COVID-19); Influenza, Human; Kidney Neoplasms; Lymphoma; Melanoma; Mesothelioma; Mismatch Repair Deficient Cancer; Neoplasm Metastasis; Neoplasms; Skin Neoplasms; Solid tumours; Tuberculosis | Details |
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Lifitegrast | SHP-606; SAR-1119; SAR-1118; SPD-606; OJL-332 | Approved | Shire Development Llc | Xiidra, 朗悦明 | United States | Dry Eye Syndromes | Bausch And Lomb Inc | 2016-07-11 | Conjunctivitis, Allergic; Diabetic macular oedema; Dry Eye Syndromes; Graft vs Host Disease; Keratoconjunctivitis Sicca; Xerophthalmia | Details |